TP53 and cancer: In our previous report [15], we showed that treatment with the progestin-depot medroxyprogesterone acetate (DMPA) significantly reduced the cross-sectional area of the fallopian tube in the mogp-TAg mice by inhibiting the expansion of p53 signatures, STIC lesions, and cancer in the FT epithelial layer.